Yield10 Bioscience, Inc.
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 is leveraging an extensive track record of innovation based around optimizing the flow of carbon in living systems. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing seed production, Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and corn. Yield10 is based in Woburn, MA.YEAR FOUNDED:
1992
LEADERSHIP:
CEO: Oliver P. Peoples
CAO: Charles B. Haaser
CSO: Kristi Snell
FOLLOW YIELD10 BIOSCIENCE:
Tweets by Yield10 Bioscience
39 articles with Yield10 Bioscience, Inc.
-
Yield10 Bioscience Announces Start of Field Tests of Winter Camelina Varieties
10/28/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties.
-
Yield10 Bioscience Announces Participation at The H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)
9/9/2020
Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference. The conference is being held on September 14-16, 2020 virtually. Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10, will provide an overview of the Company's business during the live presentation on Monday, September 14, 2
-
Yield10 Bioscience Announces Closing of $4.0 Million Public Offering, Including Exercise of the Over-Allotment Option, and Concurrent $1.7 Million Private Placement
8/26/2020
Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share. In addition, Maxim Group LLC has exercised its over-allotment option to purchase 116,835 shares of common stock, at the public offering price less underwriting discounts. Gross proceeds before deductin
-
Yield10 Bioscience Announces Pricing of $5.2 Million Public Offering and Concurrent Private Placement
8/23/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, announced the pricing of its underwritten public offering of 835,000 shares of its common stock at a public offering price of $4.25 per share.
-
Yield10 Bioscience Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
8/21/2020
Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced it has commenced an underwritten public offering of shares of its common stock.
-
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulated Status of its CRISPR Genome-Edited C3007 Trait in Canola; Plans U.S. Field Tests for 2021
8/17/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited trait C3007 in canola plant lines developed for increased oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website . In June 2020, Yield10 submitted an “Am I regulated?” let
-
Yield10 Bioscience Signs Research Agreement with GDM to Evaluate New Yield Traits in Soybean
8/11/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has signed a three-year non-exclusive research agreement with GDM (“GDM”), a company specialized in plant genetics based in Gibson City, Illinois to evaluate novel yield traits in soybean. Under the agreement, GDM plans to work with Yield10 yield traits within its research and development program for soybean as a strategy t
-
Yield10 Bioscience Announces Second Quarter 2020 Financial Results
8/11/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and six months ended June 30, 2020.
-
Yield10 Bioscience to Announce Second Quarter 2020 Financial Results and Host a Conference Call on Tuesday, August 11, 2020
8/6/2020
Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its second quarter 2020 financial results and provide a corporate update on Tuesday, August 11, 2020. Management will host a conference call on Tuesday, August 11, 2020 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, ther
-
Yield10 Bioscience Announces Spring Planting of 50 Acres of Wild-Type Spring Camelina to Support Business Development Plans
8/5/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it established 50 acres of spring Camelina under contract with a grower in Montana in the second quarter of 2020.
-
Yield10 Bioscience Announces Successful Evaluation of Emergence and Establishment in Field Tests of Winter Camelina Varieties
8/4/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it conducted field testing during the 2019/2020 winter season to evaluate emergence of winter Camelina sativa varieties. Yield10 is developing double haploid lines as a foundation for Camelina development and breeding for crossing in new performance traits. The testing of these winter varieties is part of Yield10’s development of Camelina sativa
-
Yield10 Bioscience Begins 2020 Field Test Program to Evaluate Novel Yield Traits in Camelina and Canola
6/17/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has begun its 2020 Field Test Program based on the recent completion of planting at all sites contracted for the trials in the United States and Canada. Yield10’s 2020 Field Test Program is designed to evaluate several novel traits in Camelina and canola and the Company expects to harvest the plants and begin reporting data from the field tests in the
-
Yield10 Bioscience Secures Regulatory Permits for U.S. and Canadian Sites and Announces Plans for 2020 Field Test Program in Camelina and Canola
5/14/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, announced that the Company has secured all of the regulatory permits required to conduct field tests for multiple traits at sites in the United States and Canada contracted for the 2020 growing season.
-
Yield10 Bioscience Announces First Quarter 2020 Financial Results
5/14/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three months ended March 31, 2020.
-
Yield10 Bioscience to Announce First Quarter 2020 Financial Results and Host a Conference Call on Thursday, May 14, 2020
5/13/2020
Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its first quarter 2020 financial results and provide a corporate update on Thursday, May 14, 2020. Management will host a conference call on Thursday, May 14, 2020 at 6:00 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management’s formal remarks, there will
-
Yield10 Bioscience Announces Change of 2020 Annual Meeting of Stockholders to a Virtual Meeting
5/6/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, announced today a change in the format of its Annual Meeting of Shareholders ("Annual Meeting") from an in-person to a virtual-only meeting, via webcast, due to the emerging public health impact of the coronavirus pandemic (COVID-19) and to support the health and well-being of the Company's shareholders, employees and their families. As previously announced, the Annual M
-
Yield10 Bioscience Obtains Positive Response from USDA-APHIS on Regulatory Status of its CRISPR Genome-Edited C3007 Trait in Camelina, Paving the Way for U.S. Field Tests
4/27/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited C3007 trait in Camelina sativa plant lines designed to increase oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website . In January 2020, Yield10 submitted an “Am I Regula
-
Yield10 Bioscience Announces Results of 2019 Field Test Program
3/19/2020
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced the results from field tests conducted in the 2019 growing season in the United States and Canada.
-
Yield10 Bioscience Announces Fourth Quarter and Full Year 2019 Financial Results
3/19/2020
Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the three and twelve months ended December 31, 2019.
-
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2019 Financial Results and Host a Conference Call on Thursday, March 19, 2020
3/12/2020
Yield10 Bioscience, Inc. (NASDAQ: YTEN), an agricultural bioscience company, announced today that the Company will report its fourth quarter and full year 2019 financial results and provide a corporate update on Thursday, March 19, 2020.